Publication date: Sep 10, 2019
Following Ocrevus treatment, blood neurofilament light chain (NfL) levels were lowered to a healthy donor range  in relapsing MS (RMS) and primary progressive MS (PPMS) patients.
In the Phase III OPERA I study in RMS and the ORATORIO study in PPMS, blood NfL levels were significantly lower after treatment with Ocrevus.
|disease||MESH||primary progressive multiple sclerosis|
|disease||DOID||primary progressive multiple sclerosis|
- Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
- Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies